StockNews.com Downgrades Adaptimmune Therapeutics (NASDAQ:ADAP) to Buy

Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.

Separately, HC Wainwright dropped their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday.

Adaptimmune Therapeutics Trading Down 23.3 %

Adaptimmune Therapeutics stock traded down $0.18 during trading on Thursday, hitting $0.59. The company’s stock had a trading volume of 14,509,965 shares, compared to its average volume of 1,689,404. The stock has a market capitalization of $151.19 million, a price-to-earnings ratio of -1.69 and a beta of 2.26. The stock’s fifty day moving average is $0.89 and its 200 day moving average is $1.04. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.09.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Monday, August 12th. The biotechnology company reported $0.27 EPS for the quarter. The firm had revenue of $128.23 million during the quarter, compared to analyst estimates of $58.00 million. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. As a group, equities research analysts predict that Adaptimmune Therapeutics will post -0.23 EPS for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Large investors have recently modified their holdings of the stock. Vontobel Holding Ltd. boosted its holdings in Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the last quarter. Fullcircle Wealth LLC bought a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $33,000. FMR LLC increased its position in Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares during the period. Boulder Hill Capital Management LP acquired a new stake in Adaptimmune Therapeutics in the 1st quarter valued at approximately $143,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at $95,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.